Enhanced In Vitro/In Vivo Cytotoxicity Against Burkitt Lymphoma/Primary Mediastinal Large B Cell Lymphoma by Polatuzumab Vedotin (hu- anti-CD79b-vc-MMAE, PV) Alone or in Combination with Obinutuzumab
Author Type(s)
Faculty, Resident/Fellow
Document Type
Abstract
Publication Date
7-2018
Journal Title
Cancer Research
Department
Pediatrics
Second Department
Health Behavior and Community Health
Recommended Citation
Tiwari, A. A., Edani, D., Azmy, C., Ayello, J., Klein, C., & Cairo, M. S. (2018). Enhanced In Vitro/In Vivo Cytotoxicity Against Burkitt Lymphoma/Primary Mediastinal Large B Cell Lymphoma by Polatuzumab Vedotin (hu- anti-CD79b-vc-MMAE, PV) Alone or in Combination with Obinutuzumab. Cancer Research, 78 (13 Suppl.), 1778. https://doi.org/10.1158/1538-7445.AM2018-1788
COinS
